H.C. Wainwright & Co. Research
Advisory Approach
H.C. Wainwright & Co. is one of the country's oldest financial institutions, founded in 1868 and headquartered in New York City. The firm operates with a mission to provide institutional-quality investment banking, capital markets advisory, and equity research services to emerging growth companies, particularly in the life sciences and healthcare sectors. H.C. Wainwright's core thesis is that high-growth, innovative companies in healthcare and biotechnology require sophisticated capital markets support and institutional investor distribution to fund development and scale operations. The firm differentiates through deep sector expertise, comprehensive institutional relationships, and a proven track record in executing complex capital raises and strategic transactions.
Market Position and Track Record
H.C. Wainwright has established itself as the dominant player in the PIPE (private investment in public equity), RD (registered direct offering), and CMPO (confidentially marketed public offering) markets. The firm is ranked #1 placement agent by transaction volume for 12 consecutive years according to PlacementTracker, a division of EPFR. In 2025 alone, H.C. Wainwright executed 345 transactions totaling approximately $78.9 billion in aggregate transaction value. This volume demonstrates the firm's unparalleled execution capability in capital markets advisory and placement agent services.
Cumulatively since 1998, H.C. Wainwright has maintained the #1 ranking for PIPE and RD transactions, a position of market leadership that spans more than 25 years. This consistency reflects both the firm's specialized expertise and the trust that emerging growth companies place in the firm to execute capital raises efficiently.
Sector Focus and Industry Expertise
H.C. Wainwright concentrates on biotechnology, pharmaceutical, medical device, healthcare services, and life sciences companies. The firm maintains one of the largest dedicated equity research teams focused on small- to mid-cap healthcare and biotech companies, with analysts covering hundreds of public companies in these sectors. The firm's research team includes Managing Director-level analysts with 15+ years of sector-specific experience, including former biotech industry practitioners who bring operational and technical understanding to their coverage.
The firm's focus on early-stage and emerging growth healthcare companies positions it at the critical intersection of drug development, commercialization, and capital formation. Clients range from clinical-stage therapeutics companies conducting early clinical trials to established public biotech firms seeking to fund pipeline advancement or pursue strategic acquisitions.
Capital Markets Advisory Services
H.C. Wainwright's primary service offering is institutional equity capital raising through multiple mechanisms:
- PIPE (Private Investment in Public Equity): Confidential direct placements of equity with institutional investors, executed without public marketing
- Registered Direct Offerings (RD): SEC-registered direct offerings to accredited institutional investors, combining speed with regulatory compliance
- Confidentially Marketed Public Offerings (CMPO): Limited auction processes combining confidentiality with broad institutional participation
- Traditional Underwritten Offerings: Full underwriting services for public equity and debt issuances
- Debt Advisory: Structured debt and convertible offerings for healthcare and biotech companies
The firm's execution model emphasizes rapid capital sourcing (30-90 days for most placements), institutional investor quality, and minimal public disclosure where permitted. This is particularly valuable for companies in sensitive development phases (regulatory decisions, clinical trial results, partnering negotiations) where public marketing would create competitive or operational risk.
Institutional Investor Network
H.C. Wainwright maintains relationships with over 1,000 active institutional investors, including:
- Dedicated healthcare and life sciences mutual funds (250+ dedicated healthcare funds in its network)
- Healthcare-focused hedge funds and specialized investment vehicles
- Family offices and ultra-high-net-worth individuals with life sciences mandates
- Public pension funds with healthcare allocations
- International institutional investors seeking US biotech exposure
This distribution network is built through 25+ years of consistent execution, institutional research coverage, and corporate access programming. The firm's annual Global Investment Conference (now in its 27th edition) hosts 1,000+ institutional investors and company management teams, further deepening relationships and deal sourcing.
Advisory Team and Expertise
The firm is led by CEO Mark E. Kaplan (appointed July 2025), who brings extensive investment banking background from Cantor Fitzgerald. Executive Vice Chairman Mark Viklund continues to guide strategic direction. The M&A and strategic advisory practice is headed by Managing Directors Will Hoh, Alan Jakimo, and Russ Steward, all of whom joined in 2020 to strengthen the firm's advisory capabilities.
The equity research division is led by David Lenchus (Director of Equity Research), with 20+ years of research management experience. The team includes Managing Directors with deep sector expertise, including life sciences analysts with 15+ years of biotech coverage experience and former biotech professionals who contribute operational insight.
Jim Horvath, Managing Director of Healthcare Equities Sales, joined in January 2026 from Piper Sandler, bringing 25+ years of institutional healthcare sales experience and immediately strengthening the firm's healthcare equities distribution platform.
Competitive Positioning
H.C. Wainwright competes primarily on three dimensions:
-
Specialization: Unlike generalist banks, H.C. Wainwright focuses almost exclusively on healthcare, biotech, and emerging growth companies. This allows deep sector expertise and efficient capital sourcing within a known investor base.
-
Speed and Efficiency: PIPE and RD transactions executed by H.C. Wainwright typically close in 30-90 days, compared to 120-180 days for traditional underwritten offerings. This speed is valuable for capital-efficient companies where time-to-capital directly impacts development timelines.
-
Institutional Investor Depth: The firm's 25+ year track record in PIPE/RD placements means it has unparalleled relationships with institutional investors active in healthcare investing. Investors trust H.C. Wainwright to source quality deal flow and provide quality research support.
-
Research Coverage: H.C. Wainwright's equity research team covers 200+ small-cap and mid-cap biotech and healthcare companies, a coverage breadth matched by few other firms. This research creates an ongoing relationship with institutional investors and supports deal execution.
Not a Traditional M&A Advisory Firm
Important to note: H.C. Wainwright is not a traditional lower-middle-market M&A advisory firm in the Lehman-fee sense. The firm does not typically execute sell-side M&A processes, sell company ownership stakes, or advise on acquisition strategy for large private equity firms or corporate strategic buyers. Instead, H.C. Wainwright specializes in capital markets advisory for public and near-public companies, including equity offerings, debt structuring, strategic placements, and investor relations support.
The firm has limited historical M&A advisory engagement (one documented engagement: Alliqua BioMedical asset sale to Celularity in 2018), and M&A is not a primary revenue line. Companies seeking traditional M&A advisory with a full-process sell-side engagement, buyer network development, and valuation support should engage specialist M&A advisory firms.
Regulatory and Compliance
H.C. Wainwright is a FINRA and SIPC member, operating under strict regulatory oversight. The firm is registered with the SEC (SEC# 8-43115) and maintains CRD# 375 with FINRA. The firm has been a registered broker-dealer for decades with a clean disciplinary record. Compliance and legal operations are led by Chief Legal Officer Merav Gershtenman.
Geographic Coverage
H.C. Wainwright is US-based with headquarters at 430 Park Avenue, New York. The firm operates across all major US markets and maintains relationships with international institutional investors seeking US biotech and healthcare exposure. The firm does not maintain international offices but serves a global client base of institutional investors.
Conference and Events Platform
Beyond transaction advisory, H.C. Wainwright operates the Global Investment Conference (27th annual in 2025), one of the largest investor conferences for small- to mid-cap biotech and healthcare companies. The conference draws 1,000+ attendees annually and serves as a platform for company presentations, investor education, and deal sourcing.
The firm also organizes vertical investor conferences focused on specific sectors (liver disease, oncology, etc.), further strengthening its positioning as a thought leader and connector in life sciences investing.
Summary
H.C. Wainwright & Co. is the dominant specialized investment bank for healthcare and emerging growth company capital raising. The firm's 25+ year track record in PIPE/RD execution, unparalleled institutional investor relationships in healthcare, and deep sector research coverage make it the natural choice for biotech and healthcare companies seeking rapid, efficient capital markets solutions. The firm is not a traditional M&A advisory house but excels at capital structure optimization, investor placement, and strategic equity and debt offerings. For companies in life sciences and healthcare seeking capital raise advisory, investor relations support, and institutional distribution, H.C. Wainwright remains the market leader.